-
1.
公开(公告)号:US20100111858A1
公开(公告)日:2010-05-06
申请号:US12523402
申请日:2008-01-17
申请人: Carol P. Howard , Dennis A. Moore
发明人: Carol P. Howard , Dennis A. Moore
IPC分类号: A61K31/415 , C07D231/12 , C07D403/12 , A61K51/04 , A61K31/4155 , A61K47/48 , A61P35/00
CPC分类号: A61K49/0002 , A61K51/0453
摘要: The present invention provides conjugates useful for the diagnosis and treatment of diseases associated with the over-expression of COX-2. The conjugates comprise a selective COX-2 targeting carrier, a metal coordinating moiety, and a linker chemically linking the metal coordinating moiety to the carrier. The metals coordinated by the metal coordinating moiety are selected from paramagnetic or radioisotopes. The invention also includes kits comprising a conjugate and a radioisotope solution.
摘要翻译: 本发明提供了可用于诊断和治疗与COX-2过度表达有关的疾病的缀合物。 缀合物包含选择性COX-2靶向载体,金属配位部分和将金属配位部分与载体化学连接的连接体。 由金属配位部分配位的金属选自顺磁或放射性同位素。 本发明还包括包含缀合物和放射性同位素溶液的试剂盒。
-
公开(公告)号:US20080279768A1
公开(公告)日:2008-11-13
申请号:US12094995
申请日:2006-11-29
申请人: Dennis A. Moore , Carol P. Howard
发明人: Dennis A. Moore , Carol P. Howard
IPC分类号: A61K51/10 , A61K103/20 , A61K103/10 , A61K103/34 , A61K51/08 , A61K49/14 , A61K49/16 , A61K49/10 , A61K51/04 , A61K103/40 , A61K103/00
CPC分类号: A61K51/088 , A61K49/0002 , A61K51/0453
摘要: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostics or therapeutic agents. Specifically, conjugates of the present invention include a carrier, a metal coordinating moiety, and a urea linkage chemically linking the metal coordinating moiety to the carrier. The carrier is generally utilized for targeting the conjugate to a biological tissue or organ.
摘要翻译: 本发明涉及用作金属药物诊断或治疗剂的金属螯合缀合物。 具体地,本发明的缀合物包括载体,金属配位部分和将金属配位部分与载体化学连接的脲键。 载体通常用于将缀合物靶向生物组织或器官。
-
公开(公告)号:US06890937B2
公开(公告)日:2005-05-10
申请号:US10337942
申请日:2003-01-07
申请人: Thomas E. Barta , Daniel P. Becker , Louis J. Bedell , Terri L. Boehm , Jeffery N. Carroll , Gary A. DeCrezcenzo , Theresa R. Fletcher , John N. Freskos , Daniel P. Getman , Gunnar J. Hanson , Susan L. Hockerman , Carol P. Howard , Stephen A. Kolodziej , Madeleine H. Li , Joseph J. McDonald , Deborah A. Mischke , Patrick B. Mullins , Joseph G. Rico , Nathan W. Stehle , Clara I. Villamil
发明人: Thomas E. Barta , Daniel P. Becker , Louis J. Bedell , Terri L. Boehm , Jeffery N. Carroll , Gary A. DeCrezcenzo , Theresa R. Fletcher , John N. Freskos , Daniel P. Getman , Gunnar J. Hanson , Susan L. Hockerman , Carol P. Howard , Stephen A. Kolodziej , Madeleine H. Li , Joseph J. McDonald , Deborah A. Mischke , Patrick B. Mullins , Joseph G. Rico , Nathan W. Stehle , Clara I. Villamil
IPC分类号: A61K31/16 , A61K31/167 , A61K31/27 , A61K31/35 , A61K31/351 , A61K31/357 , A61K31/366 , A61K31/38 , A61K31/381 , A61K31/382 , A61K31/39 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/444 , A61K31/445 , A61K31/4465 , A61K31/4525 , A61K31/454 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5375 , A61K31/54 , A61K31/541 , A61P1/02 , A61P1/04 , A61P9/10 , A61P13/00 , A61P19/00 , A61P19/02 , A61P25/28 , A61P27/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P43/00 , C07C317/44 , C07C319/06 , C07D211/66 , C07D211/94 , C07D211/96 , C07D239/04 , C07D279/06 , C07D309/08 , C07D309/12 , C07D319/06 , C07D327/02 , C07D333/38 , C07D335/02 , C07D337/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D521/00 , C07D211/06
CPC分类号: C07D231/12 , A61K31/19 , A61K31/4166 , A61K31/421 , A61K31/426 , C07C317/44 , C07D207/48 , C07D211/54 , C07D211/66 , C07D211/86 , C07D211/94 , C07D211/96 , C07D225/02 , C07D233/56 , C07D239/04 , C07D249/08 , C07D263/06 , C07D265/06 , C07D279/06 , C07D281/08 , C07D309/08 , C07D309/28 , C07D319/06 , C07D325/00 , C07D335/02 , C07D337/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.
摘要翻译: 公开了一种处理方法,其包括施用有效量的显示出一种或多种基质金属蛋白酶(MMP)酶如MMP-2,MMP-9和MMP-13的优异抑制活性的芳香族砜异羟肟酸,同时显示 至少对具有与病理基质金属蛋白酶活性相关的病症的宿主的MMP-1的抑制显着降低。 施用的酶抑制剂在结构上对应于下式(I)或其药学上可接受的盐,其中R 1和R 2都是氢或R 2, 1和R 2与它们所键合的原子一起形成在环中含有一个,两个或三个杂原子的5-至8-元环,其为氧,硫, 或氮气。 式(I)中的R 3是任选取代的芳基或任选取代的杂芳基。 还公开了具有这些选择活性的金属蛋白酶抑制剂化合物,制备这种化合物的方法和使用抑制剂的药物组合物。
-
-